Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

Premium: Of Sun Pharma, Infy and Some Results That Spooked The Day

Sunpharma is down 13% today after announcing that things after the Ranbaxy acquisition aren’t exactly rosy. They had a conference call yesterday in ...

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial